journal
https://read.qxmd.com/read/37770770/efficacy-and-safety-of-single-pill-combination-of-rosuvastatin-and-ezetimibe-in-chinese-patients-with-primary-hypercholesterolemia-inadequately-controlled-by-statin-treatment-rozel-a-randomized-double-blind-double-dummy-active-controlled-phase-3-clinical-trial
#1
JOURNAL ARTICLE
Qiaoli Su, Ying Liu, Guogang Zhang, Li Xu, Min Wang, Shifang Mei, Genevieve Garon, Yanzhen Wu, Qiang Lv, Changsheng Ma
INTRODUCTION: Many patients with primary hypercholesterolemia do not achieve their plasma low-density lipoprotein cholesterol (LDL-C) goals with statin alone under a recommended dose of statin (e.g., 10 mg rosuvastatin) in China. The objective of this phase III study was to evaluate the efficacy and safety of a new single-pill combination (SPC) of rosuvastatin 10 mg/ezetimibe 10 mg (R10/E10) in this population. METHODS: This was a randomized, double-blind, double-dummy, active-controlled study in patients with primary hypercholesterolemia inadequately controlled with statin alone...
September 28, 2023: Advances in Therapy
https://read.qxmd.com/read/37770769/emotional-journey-of-patients-with-eosinophilic-esophagitis
#2
JOURNAL ARTICLE
Helen Larsson, Mary J Strobel, Eduardo Perez-Guagnelli
INTRODUCTION: Eosinophilic esophagitis (EoE) is a chronic and progressive disease associated with dysphagia and eosinophilic infiltration of the esophageal mucosa. EoE can have a negative impact on a patient's quality of life (QoL); however, there is very limited data reflecting the emotional journey of patients with EoE or their perceived unmet needs. The aim of this study was to determine the emotional impact of EoE on patients at each stage of the patient journey. METHODS: In this cross-sectional and qualitative research study, adult patients with EoE from eight different countries provided their experiences and feelings across each stage of the patient journey through one-on-one semi-structured interviews...
September 28, 2023: Advances in Therapy
https://read.qxmd.com/read/37768507/the-effect-of-an-interdisciplinary-dermatological-rheumatological-consultation-on-the-outcome-of-patients-with-psoriasis-with-musculoskeletal-pain-a-prospective-single-center-cohort-study
#3
JOURNAL ARTICLE
Jan Alwin von Ahnen, Georg Gross, Christian Lull, Mara Blauth, Bernhard Kraemer, Victor Olsavszky, Jan Leipe, Astrid Schmieder
INTRODUCTION: Psoriatic arthritis (PsA), a disease with complex inflammatory musculoskeletal manifestations, complicates psoriasis in up to 30% of patients. In this study, we aimed to determine the effect of an interdisciplinary dermatological-rheumatological consultation (IDRC) for patients with psoriasis with musculoskeletal symptoms. METHODS: This prospective study enrolled 202 patients with psoriasis. Patients with musculoskeletal pain (MSP) (n = 115) participated in an IDRC 12 weeks after enrollment...
September 28, 2023: Advances in Therapy
https://read.qxmd.com/read/37768506/cardiovascular-insights-for-the-appropriate-management-of-chronic-venous-disease-a-narrative-review-of-implications-for-the-use-of-venoactive-drugs
#4
REVIEW
Sergio Gianesini, Leonardo De Luca, Toni Feodor, Wassila Taha, Kursat Bozkurt, Fedor Lurie
Evidence suggests that chronic venous disease (CVD) may be a cardiovascular disorder, as patients with CVD are prone to developing arterial (atherosclerosis) and venous (thromboembolism) diseases. This may be partly explained by shared risk factors. Thus, patients with CVD or cardiovascular disease require careful history-taking and physical assessment to identify coexisting pathologies and risk factors. This article summarises a symposium at the XIX World Congress of the International Union of Phlebology held in Istanbul, Turkey, in September 2022...
September 28, 2023: Advances in Therapy
https://read.qxmd.com/read/37759150/economic-evaluation-of-a-bioinductive-implant-for-the-repair-of-rotator-cuff-tears-compared-with-standard-surgery-in-italy
#5
JOURNAL ARTICLE
Carla Rognoni, Leo M Nherera, Raffaele Garofalo, Enrico Guerra, Umile Giuseppe Longo, Ettore Taverna, Rosanna Tarricone
INTRODUCTION: Rotator cuff tear (RCT) is a painful, progressive condition resulting from damage to the rotator cuff tendons and is the leading cause of shoulder-related disability. Surgical repair of rotator cuff is an established standard of care (SOC); however, failure of the procedure can occur. In this context, the use of collagen-based bioinductive implant REGENETEN showed long-term improvements in clinical scores. The aim of the study was to assess the cost-effectiveness of REGENETEN combined with SOC (SOC + REGENETEN) compared to SOC alone from both National Healthcare Service (NHS) and societal perspectives in Italy...
September 28, 2023: Advances in Therapy
https://read.qxmd.com/read/37755602/factors-contributing-to-the-change-in-overweight-obesity-prevalence-among-indian-adults-a-multivariate-decomposition-analysis-of-data-from-the-national-family-health-surveys
#6
JOURNAL ARTICLE
Madhur Verma, Vandana Esht, Mohammed M Alshehri, Mohammed Aljahni, Kirti Chauhan, Walaa E Morsy, Nitin Kapoor, Sanjay Kalra
INTRODUCTION: Concerns over the escalating burden of non-communicable diseases call for the redressal of behavioral risk factors like increased body mass index. Most studies have failed to quantify the contribution of socio-demographic characteristics in a linear trend. The present study aims to estimate the current prevalence of overweight and obesity in Indian adults and the contribution of different socio-demographic factors to the increasing prevalence. METHODS: We carried out a secondary data analysis of two National Family Health Survey (NFHS) rounds...
September 27, 2023: Advances in Therapy
https://read.qxmd.com/read/37751025/real-world-use-safety-and-patient-experience-of-20-subcutaneous-immunoglobulin-for-primary-immunodeficiency-diseases
#7
JOURNAL ARTICLE
Maria Fasshauer, Michael Borte, Michaela Bitzenhofer, Christine Pausch, David Pittrow, Michelle Park, André Gladiator, Peter Jandus
INTRODUCTION: The CORE study aimed to provide a detailed understanding of real-world immune globulin subcutaneous (human) 20% solution (Ig20Gly) utilization in patients with primary immunodeficiency diseases (PIDs) in Germany and Switzerland. METHODS: Patients with PIDs receiving a stable dose of any subcutaneous immunoglobulin for ≥ 3 months before enrollment were eligible for this multicenter (n = 5), phase 4, non-interventional, prospective, longitudinal cohort study...
September 26, 2023: Advances in Therapy
https://read.qxmd.com/read/37751024/expert-discussion-on-challenges-in-c3g-diagnosis-a-podcast-article-on-best-practices-in-kidney-biopsies
#8
JOURNAL ARTICLE
Richard A Lafayette, Vivek Charu
Complement 3 glomerulopathy (C3G) is an ultra-rare, progressive kidney disease resulting from dysregulation of the alternative complement pathway. Clinical presentation of C3G is heterogeneous and definitive diagnosis relies on kidney biopsy and immunofluorescence staining. The term C3G encompasses two subgroups, dense deposit disease and C3 glomerulonephritis, distinguished via electron microscopy. In this podcast article, the authors discuss the challenges associated with C3G diagnosis and the central role of kidney biopsy...
September 26, 2023: Advances in Therapy
https://read.qxmd.com/read/37751023/symptom-and-treatment-satisfaction-in-members-of-the-us-and-canadian-gbs-cidp-foundations-with-a-diagnosis-of-chronic-inflammatory-demyelinating-polyneuropathy
#9
JOURNAL ARTICLE
Meg Mendoza, Christopher Tran, Vera Bril, Hans D Katzberg, Carolina Barnett-Tapia
INTRODUCTION: Current guidelines for defining good outcomes in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) are predominately defined by experts. At present, we do not have a patient-anchored definition of what constitutes a "good" outcome. Our study aimed to assess the symptom burden of people living with CIDP, as well as satisfaction with treatments and clinical outcomes. METHODS: We conducted an online-survey in CIDP patients registered with the US and Canadian GBS/CIDP foundations...
September 26, 2023: Advances in Therapy
https://read.qxmd.com/read/37751022/effect-of-nintedanib-in-patients-with-progressive-pulmonary-fibrosis-in-subgroups-with-differing-baseline-characteristics
#10
JOURNAL ARTICLE
Martin Kolb, Kevin R Flaherty, Rafael S Silva, Antje Prasse, Carlo Vancheri, Heiko Mueller, Kamila Sroka-Saidi, Athol U Wells
INTRODUCTION: In the INBUILD trial in patients with progressive pulmonary fibrosis other than idiopathic pulmonary fibrosis (IPF), nintedanib slowed the rate of decline in forced vital capacity (FVC; mL/year) over 52 weeks compared with placebo. We assessed the efficacy of nintedanib across subgroups in the INBUILD trial by baseline characteristics. METHODS: We assessed the rate of decline in FVC over 52 weeks and time to progression of interstitial lung disease (ILD) (absolute decline from baseline in FVC % predicted > 10%) or death over the whole trial in subgroups based on sex, age, race, body mass index (BMI), time since diagnosis of ILD, FVC % predicted, diffusing capacity of the lungs for carbon monoxide (DLco) % predicted, composite physiologic index (CPI), GAP (gender, age, lung physiology) stage, use of anti-acid therapy and use of disease-modifying antirheumatic drugs (DMARDs) at baseline...
September 26, 2023: Advances in Therapy
https://read.qxmd.com/read/37751021/comparative-efficacy-durability-and-safety-of-faricimab-in-the-treatment-of-diabetic-macular-edema-a-systematic-literature-review-and-network-meta-analysis
#11
JOURNAL ARTICLE
Claire Watkins, Tatiana Paulo, Christian Bührer, Nancy M Holekamp, Marloes Bagijn
INTRODUCTION: A systematic literature review (SLR) and network meta-analysis (NMA) were conducted to evaluate the comparative efficacy, durability and safety of faricimab, used in a Treat & Extend (T&E) regime with intervals up to every 16 weeks (Q16W), relative to other therapies currently in use for treatment of diabetic macular oedema (DME). Of particular interest were anti-vascular endothelial growth factor (VEGF) therapies applied in flexible dosing regimens such as Pro re nata (PRN) and T&E, which are the mainstay in clinical practice...
September 26, 2023: Advances in Therapy
https://read.qxmd.com/read/37740832/real-world-hemoglobin-a1c-changes-prescribing-provider-types-and-medication-dose-among-patients-with-type-2-diabetes-mellitus-initiating-treatment-with-oral-semaglutide
#12
JOURNAL ARTICLE
Monica Frazer, Caroline Swift, Noelle N Gronroos, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J Dunn, Josh Noone, Mico Guevarra
INTRODUCTION: Given the lack of real-world data on oral semaglutide use outside clinical trials, the purpose of this study was to describe dose, prescriber specialty, and change in hemoglobin A1c (HbA1c) after 6 months of oral semaglutide treatment for patients with type 2 diabetes mellitus (T2DM). METHODS: This was a retrospective study among adult patients with T2DM with ≥ 1 claim for oral semaglutide between November 1, 2019`1-June 30, 2020...
September 23, 2023: Advances in Therapy
https://read.qxmd.com/read/37737889/the-epidemiology-of-palmoplantar-pustulosis-an-analysis-of-multiple-health-insurance-claims-and-electronic-health-records-databases
#13
JOURNAL ARTICLE
Darmendra Ramcharran, Bruce Strober, Kenneth Gordon, Cynthia DeKlotz, Steven Fakharzadeh, Ya-Wen Yang, Joel Swerdel, Jill Hardin, Sridhar Dronavalli, Amy S Paller
BACKGROUND: Palmoplantar pustulosis (PPP) is a chronic inflammatory condition characterized by sterile pustules on the palms and soles. This study evaluated the epidemiology of PPP using claims and electronic health record (EHR) databases. METHODS: Patients coded for PPP in the United States (US) and Japan from 2016 to 2020 were identified. Several PPP definitions were evaluated; the specific definition (≥ 2 visits coded for PPP, the second 31-730 days after diagnosis) was chosen for characterizing PPP epidemiology...
September 22, 2023: Advances in Therapy
https://read.qxmd.com/read/37733212/the-adherence-and-outcomes-benefits-of-using-a-connected-reusable-auto-injector-for-self-injecting-biologics-a-narrative-review
#14
REVIEW
Attila Antalfy, Kyle Berman, Claire Everitt, Rieke Alten, Mark Latymer, Charles M Godfrey
Many biologics are now self-administered by patients at home. A variety of self-injection devices are available, including vials and syringes, prefilled syringes, and spring-driven prefilled pens or auto-injectors. Each has advantages and drawbacks, and different devices suit different patients. For example, some patients have difficulty achieving consistent and successful self-injection due to poor manual dexterity, or experience anxiety at the prospect of self-injection or injection-site pain. These factors can reduce patients' medication adherence and overall experience...
September 21, 2023: Advances in Therapy
https://read.qxmd.com/read/37733211/efficacy-and-safety-of-esaxerenone-in-hypertensive-patients-with-diabetes-mellitus-undergoing-treatment-with-sodium-glucose-cotransporter%C3%A2-2-inhibitors-eagle-dh
#15
JOURNAL ARTICLE
Hirohiko Motoki, Yoshito Inobe, Toshiki Fukui, Arata Iwasaki, Shinya Hiramitsu, Sekiya Koyama, Izuru Masuda, Noriyuki Sekimura, Kazuya Yamamoto, Ai Sato, Mitsuhisa Komatsu, Takashi Taguchi, Kazuhito Shiosakai, Kotaro Sugimoto, Koichiro Kuwahara
INTRODUCTION: The EAGLE-DH study assessed the efficacy and safety of esaxerenone in hypertensive patients with diabetes mellitus receiving sodium-glucose cotransporter 2 (SGLT2) inhibitors. METHODS: In this multicenter, open-label, prospective, interventional study, esaxerenone was started at 1.25 or 2.5 mg/day and could be gradually increased to 5 mg/day on the basis of blood pressure (BP) and serum potassium levels. Oral hypoglycemic or antihypertensive medications prior to obtaining consent was continued...
September 21, 2023: Advances in Therapy
https://read.qxmd.com/read/37730949/comparing-cardiovascular-outcomes-and-costs-of-perindopril-enalapril-or-losartan-based-antihypertensive-regimens-in-south-africa-real-world-medical-claims-database-analysis
#16
JOURNAL ARTICLE
Jacques R Snyman, Freedom Gumedze, Erika S W Jones, Olufunke A Alaba, Nqoba Tsabedze, Alykhan Vira, Ntobeko A B Ntusi
INTRODUCTION: Differences in class or molecule-specific effects between renin-angiotensin-aldosterone system (RAAS) inhibitors have not been conclusively demonstrated. This study used South African data to assess clinical and cost outcomes of antihypertensive therapy with the three most common RAAS inhibitors: perindopril, losartan and enalapril. METHODS: Using a large, South African private health insurance claims database, we identified patients with a hypertension diagnosis in January 2015 receiving standard doses of perindopril, enalapril or losartan, alone or in combination with other agents...
September 21, 2023: Advances in Therapy
https://read.qxmd.com/read/37728697/real-world-treatment-patterns-among-patients-with-connective-tissue-disorder-related-pulmonary-arterial-hypertension-in-the-united-states-a-retrospective-claims-based-analysis
#17
JOURNAL ARTICLE
Therese Sargent, Yuen Tsang, Sumeet Panjabi, Vienica Funtanilla, Hayley D Germack, Marjolaine Gauthier-Loiselle, Ameur M Manceur, Martin Cloutier, Patrick Lefebvre
INTRODUCTION: Connective tissue disorders (CTDs) are the most frequent diseases associated with pulmonary arterial hypertension (PAH). Despite advances in treatment, the prognosis of CTD-related PAH remains poor. To help identify areas for improvement in the management of CTD-related PAH, this study assessed real-world PAH treatment patterns in this population in the US. METHODS: Eligible adult patients with PAH initiated on a PAH treatment (index date: 1st initiation date) were identified from Optum's de-identified Clinformatics® Data Mart Database (10/01/2015-09/30/2021) and categorized into mutually exclusive cohorts (CTD + PAH; PAH) based on the presence of CTD diagnosis claims...
September 20, 2023: Advances in Therapy
https://read.qxmd.com/read/37728696/vein-step-a-prospective-observational-international-study-to-assess-effectiveness-of-conservative-treatments-in-chronic-venous-disease
#18
JOURNAL ARTICLE
Zoubida Tazi Mezalek, Toni Feodor, Larisa Chernukha, Zhong Chen, Ana Rueda, Ignacio Escotto Sánchez, Alejandro José González Ochoa, Joanna Chirol, Vanessa Blanc-Guillemaud, Caroline Lohier-Durel, Jorge Hernando Ulloa
INTRODUCTION: VEIN STEP was conducted to collect international data on the management of chronic venous disease (CVD) and to assess the effectiveness of conservative treatments for the relief of CVD signs and symptoms. METHODS: This international, observational, prospective, longitudinal, cohort study recruited adult outpatients consulting for symptomatic CVD. The primary objective was the effectiveness of conservative treatments on symptoms, signs and quality of life in a real-life setting assessed using a range of patient-reported outcome measures: 10-cm Visual Analog and Patient Global Impression of Change scales for symptoms; Venous Clinical Severity Score for physician assessment of signs; and 14-item ChronIc Venous Insufficiency Questionnaire (CIVIQ-14) for quality of life...
September 20, 2023: Advances in Therapy
https://read.qxmd.com/read/37728695/corticosteroid-use-and-adherence-in-patients-treated-with-acthar-gel-for-advanced-sarcoidosis
#19
JOURNAL ARTICLE
Kyle Hayes, John Niewoehner, J Bradford Rice, Nathaniel Downes, Ella Hagopian, Izzy Ma, George J Wan
INTRODUCTION: Long-term corticosteroid use in immune-mediated diseases is associated with increased risk of adverse events (AEs) and worsened health-related quality of life (HRQoL). Previous studies report chronic high-dose corticosteroid therapy results in higher rates of healthcare resource use and AE-related medical costs. Recent studies suggest Acthar® Gel (repository corticotropin injection) is an effective steroid-sparing therapy for sarcoidosis. This study compares the corticosteroid-sparing effect between Acthar Gel and comparators and evaluates the impact of Acthar Gel adherence on reduction of corticosteroid burden...
September 20, 2023: Advances in Therapy
https://read.qxmd.com/read/37728694/genetic-evidence-supporting-a-causal-association-between-mtor-dependent-eif-4e-circulating-protein-level-and-osteoporosis
#20
JOURNAL ARTICLE
Ting Cheng, Yao-Chen Zhang, Ke-Yi Fan, Jing-Xi Hu, Qian Wang, Qi Wang, Liu Liu, He-Yi Zhang, Yao-Pu Hou, Xiao-Feng Li, Sheng-Xiao Zhang
INTRODUCTION: The mechanistic target of rapamycin (mTOR) regulates bone homeostasis, a crucial factor in osteoporosis (OP) development. However, most research is based on observational studies, and the causality remains uncertain. Therefore, we analyzed two samples of mendelian randomization (MR) to determine whether there is a causal relationship between mTOR-dependent circulating proteins and OP. METHODS: Mendelian weighting (weighted median [WM], inverse variance weighting [IVW], and MR-Egger regression) were applied to analyze the causality between bone phenotypes (bone mineral density [BMD] in forearm, femoral neck, lumbar spine, and heel) and mTOR-dependent circulating proteins (RP-S6K, 4EBP, EIF-4E, EIF-4A, and EIF-4G)...
September 20, 2023: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.